| Disease | Prevalence Estimate | US people estimate | Statistic Used for Calculation |
| Mitochondrial disorders |
N/A |
N/A |
No information
|
| Metabolic disorders |
N/A |
N/A |
No information
|
| Aging |
N/A |
N/A |
No information
|
| Diabetes |
approx 1 in 17 or 5.88% or 16 million people in USA |
15,999,999 |
16 million Americans with 10.3 million diagnosed and 8.1 million women (NWHIC); 65 per 1000 - NHIS95; 8 million - perhaps 16 million if include not-yet-diagnosed.
|
| Insulin Resistance |
approx 1 in 4 or 25.00% or 68 million people in USA |
68,000,000 |
about 25% of the USA population have insulin resistance
|
| Metabolic Syndrome |
approx 1 in 4 or 25.00% or 68 million people in USA |
68,000,000 |
about 25% of the USA population have insulin resistance
|
| Systemic lupus erythematosus |
approx 1 in 194 or 0.51% or 1.4 million people in USA |
1,400,000 |
1.4 million people in the United States, 1 in 85 (NWHIC)
|
| Diabetes Insipidus |
N/A |
N/A |
No information
|
| Cushing's syndrome |
approx 1 in 500,000 or 0.00% or 543 people in USA |
2,720 |
2-5 per million (NIDCD); 10 per million; 10-15 per million
|
| Hypertension |
approx 1 in 5 or 18.38% or 50 million people in USA |
49,999,999 |
50 million Americans (NHLBI); 217 per 1000 (NHIS95)
|
| Hypercholesterolemia |
approx 1 in 3 or 37.13% or 101 million people in USA |
101,000,004 |
estimated 101 million Americans have cholesterol >= 200 mg/dL (CDC)
|
| Hemochromatosis |
approx 1 in 272 or 0.37% or 1 million people in USA |
999,999 |
more than 1 million Americans (CDC); 5 per 1000 in Caucasians (NIDDK); 1-in-200 to 1-in-300
|
| Wilson's Disease |
approx 1 in 30,000 or 0.00% or 9,066 people in USA |
9,066 |
approximately 1 per 30,000 people suffer from Wilson disease, Genetics Home Reference website
|
| Addisonian crisis |
N/A |
N/A |
No information
|
| Alkalosis |
N/A |
N/A |
No information
|
| Acidosis |
N/A |
N/A |
No information
|
| Anaphylaxis |
N/A |
N/A |
No information
|
| Hangover |
N/A |
N/A |
No information
|
| Pituitary conditions |
N/A |
N/A |
No information
|
| Atherosclerosis |
approx 1 in 58 or 1.70% or 4.6 million people in USA |
4,624,000 |
17 per 1000 - NHIS95
|
| Diabetes Mellitus, Insulin-Dependent, Susceptibility to, 17 |
N/A |
N/A |
No information
|
| Physical conditions |
N/A |
N/A |
No information
|
| Chronic Illness |
approx 1 in 3 or 33.09% or 90 million people in USA |
89,999,996 |
90 million people in USA (CDC)
|
| Paralysis |
approx 1 in 111 or 0.90% or 2.4 million people in USA |
2,447,999 |
9 per 1000 - NHIS95 (paralysis of extremeties complete/partial)
|
| Multiple Sclerosis, Susceptibility To, 1 |
N/A |
N/A |
No information
|
| Multiple Sclerosis, Susceptibility To, 2 |
N/A |
N/A |
No information
|
| Multiple Sclerosis, Susceptibility To, 3 |
N/A |
N/A |
No information
|
| Multiple Sclerosis, Susceptibility To, 4 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 12 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 11 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 10 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 9 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 8 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 7 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 6 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 5 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 4 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 3 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 2 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 1 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus with Vitiligo, Susceptibility to, 1 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus with Hemolytic Anemia, Susceptibility to, 1 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus with Nephritis, Susceptibility to, 1 |
N/A |
N/A |
No information
|
| Systemic Lupus Erythematosus, Susceptibility to, 13 |
N/A |
N/A |
No information
|
| Metabolic syndrome (syndrome X) |
N/A |
N/A |
No information
|
| Cushing's syndrome-induced hypertension |
N/A |
N/A |
No information
|
| Systemic lupus erythematoses |
N/A |
N/A |
No information
|
| Bullous systemic lupus erythematosus |
N/A |
N/A |
No information
|
| Volume depletion |
N/A |
N/A |
No information
|
| Dehydration |
N/A |
N/A |
No information
|
| Relapsing/remitting multiple sclerosis |
N/A |
N/A |
No information
|
| Secondary chronic progressive multiple sclerosis |
N/A |
N/A |
No information
|
| Primary progressive multiple sclerosis |
N/A |
N/A |
No information
|
| Marburg multiple sclerosis |
N/A |
N/A |
No information
|
| Optic-spinal form of multiple sclerosis |
N/A |
N/A |
No information
|
| Accidental death |
N/A |
N/A |
No information
|
| Maternal death |
N/A |
N/A |
No information
|
| Systemic Juvenile Rheumatoid Arthritis |
N/A |
N/A |
No information
|
| Tuberous sclerosis |
approx 1 in 10,000 or 0.01% or 27,200 people in USA |
27,199 |
less than 1 in 10,000
|
| Balo disease |
N/A |
N/A |
No information
|
| Autoimmune Vasculitis |
N/A |
N/A |
No information
|
| Autoimmune Atherosclerosis |
N/A |
N/A |
No information
|
| Metabolic Acidosis |
N/A |
N/A |
No information
|
| Multiple Sclerosis |
approx 1 in 700 or 0.14% or 388,571 people in USA |
388,571 |
1-in-700 (NIAID)
|
| Systemic candidiasis |
N/A |
N/A |
No information
|
| Systemic mastocytosis |
N/A |
N/A |
No information
|
| Shock, Cardiogenic |
N/A |
N/A |
No information
|
| Shock, Hypovolaemic |
N/A |
N/A |
No information
|
| Shock, Neurogenic |
N/A |
N/A |
No information
|
| Shock, Septic |
N/A |
N/A |
No information
|
| Shock, Traumatic |
N/A |
N/A |
No information
|
| Shock, Obstructive |
N/A |
N/A |
No information
|
| Shock, anaphylactic |
N/A |
N/A |
No information
|
| Shock, Endocrine |
N/A |
N/A |
No information
|
| Shock, Distributive |
N/A |
N/A |
No information
|
| Wasting Syndrome |
N/A |
N/A |
No information
|
| Water Intoxication |
N/A |
N/A |
No information
|
| Systemic monochloroacetate poisoning |
N/A |
N/A |
No information
|
| Glaucoma associated with systemic abnormalities |
N/A |
N/A |
No information
|
| Renal failure-like electrolyte imbalances |
N/A |
N/A |
No information
|
| Excessive diaphoresis |
N/A |
N/A |
No information
|
| AIDS wasting syndrome |
N/A |
N/A |
No information
|
| Acute rheumatic fever |
N/A |
N/A |
No information
|
| Anoxemia |
N/A |
N/A |
No information
|
| Anoxia |
N/A |
N/A |
No information
|
| Polyarthritis, systemic |
N/A |
N/A |
No information
|
| Portuguese type amyloidosis |
N/A |
N/A |
No information
|
| Hereditary amyloidosis |
N/A |
N/A |
No information
|
| Primary amyloidosis |
N/A |
N/A |
No information
|
| Dialysis-related amyloidosis |
N/A |
N/A |
No information
|
| Amyloidosis |
approx 1 in 90,666 or 0.00% or 3,000 people in USA |
3,000 |
less than 3,000 people in the US (Mayo Clinic)
|
| A ?-protein amyloidosis |
N/A |
N/A |
No information
|
| Amyloidosis AL |
N/A |
N/A |
No information
|
| Amyloidosis beta2-microglobulinic |
N/A |
N/A |
No information
|
| Amyloidosis, inflammatory |
N/A |
N/A |
No information
|
| Immunoglobulinic amyloidosis |
N/A |
N/A |
No information
|
| Rheumatic fever |
N/A |
N/A |
No information
|
| Hereditary carnitine deficiency syndrome, systemic |
N/A |
N/A |
No information
|
| Leukocytoclastic angiitis -- systemic |
N/A |
N/A |
No information
|
| Familial Granulomatosis, Blau type |
N/A |
N/A |
No information
|
| Familial, Systemic, Juvenile Granulomatosis |
N/A |
N/A |
No information
|
| Systemic Capillary Leak Syndrome |
N/A |
N/A |
No information
|
| Scleroderma, systemic |
N/A |
N/A |
No information
|
| Spontaneous periodic hypothermia |
N/A |
N/A |
No information
|
| Hyalinosis, infantile systemic |
N/A |
N/A |
No information
|
| Aggressive systemic mastocytosis |
N/A |
N/A |
No information
|
| Cushing syndrome, familial |
N/A |
N/A |
No information
|
| Diffuse systemic sclerosi |
N/A |
N/A |
No information
|
The medical term 'prevalence' of Systemic disorders usually refers to the estimated population
of people who are managing Systemic disorders at any given time,
whereas the annual diagnosis rate of new cases of Systemic disorders is called the 'incidence'.
For more information on prevalence and incidence statistics, see about prevalence and incidence statistics.